Thursday Insights: MannKind Corporation (MNKD), Plasmatech Biopharmaceuticals Inc (PTBI), Tokai Pharmaceuticals Inc (TKAI), Box Inc (BOX)
MannKind Corporation (NASDAQ:MNKD) shares are tumbling 6.87% in mid-day trading to $5.69, adding to their 9% decline yesterday, after TheStreet’s Adam Feuerstein highlighted some red flags about the company’s inhaled insulin Afrezza and its commercial value. The columnist stated, “Since MannKind and its partner Sanofi are in the business of selling Afrezza, the fact that only six of 20 doctors are prescribing the insulin is hardly positive.”
Click Here to see the performance of columnist Adam Feuerstein.
Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) shares are up 5.5% to $7.46 in mid-day trading, after Elemer Piros, an analyst at Roth Capital, initiated a Buy rating on the stock with a $9 price target. Piros noted, “PlasmaTech, in our opinion, is assembling a world-class gene and protein therapeutics portfolio for rare genetic disorders.” According to TipRanks.com, analyst Elemer Piros has a total average return of -3.0% and a 40.0% success rate. Piros is ranked #2949 out of 3621 analysts.
Tokai Pharmaceuticals Inc (NASDAQ:TKAI) shares are on the rise Thursday, following a positive article posted on Smarter Analyst. The author, Stock Doctor, wrote, “Tokai Pharmaceuticals Galeterone addresses a huge unmet medical need in prostate cancer by targeting the high percentage of patients who are resistant to current androgen inhibitors Xtandi and Zytiga. To date, Galeterone is the only drug in development which has illustrated clinical activity against the AR-V7 variant expressed in patients with resistance.”
Click Here to see the performance of blogger Stock Doctor.
Box Inc (NYSE:BOX) shares are on the rise Thursday after the company reported a smaller-than-expected quarterly loss and raised its full-year revenue outlook on strong corporate demand for its cloud data storage products. Out of the 8 analysts polled by TipRanks, 7 rate Box stock a Hold, whereas only one rated it a Buy. With a return potential of 17.71%, the stock’s 12-month consensus target price stands at $21.67.